[Which patients from routine care use the new insulin analogue glargine U300 compared to patients with glargine U100 : A multicenter analysis of 14,123 patients with insulin glargine from die diabetes registries DPV and DIVE].

Autor: Bohn B; Institut für Epidemiologie und Medizinische Biometrie, ZIBMT, Universität Ulm, Ulm, Deutschland. barbara.bohn@uni-ulm.de.; Deutsches Diabetes Zentrum (DZD), München-Neuherberg, Deutschland. barbara.bohn@uni-ulm.de., Bramlage P; Institut für Pharmakologie und Präventive Medizin, Mahlow, Deutschland., Wagner C; Forum Diabetologie, Surheim, Deutschland., Kaltheuner M; Gemeinschaftspraxis Kaltheuner - v. Boxberg, Leverkusen, Deutschland., Welp R; Ambulanz für Diabetologie und Ernährungsmedizin, Knappschaftskrankenhaus, Bottrop, Deutschland., Sziegoleit S; Patienten Praxis Berlin Tempelhof, Berlin, Deutschland., Zimmermann A; Diabeteszentrum, Bad Aibling, Deutschland., Reuter HM; Diabetologische Schwerpunktpraxis, Jena, Deutschland., Hummel M; Diabetologische Schwerpunktpraxis, Rosenheim, Deutschland.; Institut für Diabetesforschung, Helmholtz Zentrum München, München, Deutschland., Gloyer J; Diabeteszentrum Ludwigsburg, Ludwigsburg, Deutschland., Holl RW; Institut für Epidemiologie und Medizinische Biometrie, ZIBMT, Universität Ulm, Ulm, Deutschland.; Deutsches Diabetes Zentrum (DZD), München-Neuherberg, Deutschland., Danne T; Kinder- und Jugendkrankenhaus 'AUF DER BULT', Hannover, Deutschland.
Jazyk: němčina
Zdroj: Wiener medizinische Wochenschrift (1946) [Wien Med Wochenschr] 2018 Nov; Vol. 168 (15-16), pp. 415-422. Date of Electronic Publication: 2017 Aug 21.
DOI: 10.1007/s10354-017-0589-8
Abstrakt: Background: Glargine U300 (Gla-300) is a further development of glargine U100 (Gla-100). Since 2015, Gla-300 has been available in Germany and Austria. We compared patients initiating therapy with Gla-300 with patients starting with Gla-100. Moreover, it was investigated whether patients from real-life diabetes care differ from patients participating in the EDITION clinical study program.
Methods: Data are based on the diabetes registries DPV and DIVE. Patients started/switched to Gla-100 or Gla-300 in 2015 were included. Linear regression was applied for bodyweight (BW), BMI, HbA 1C , daily total and basal insulin dose/kgBW and negative binomial regression for severe hypoglycemia. Data were adjusted for age, sex, and diabetes duration.
Results: 14,123 patients were identified (Gla-100: 11,397; Gla-300: 2726). Gla-300 patients with T1D were older, T2D patients younger compared to subjects using Gla-100 (both p < 0.0001). In Gla-300 subjects, diabetes duration was longer (both p < 0.0001). Patients started/switched to Gla-300 had a higher BW, a higher BMI and a lower baseline HbA 1C . The rate of severe hypoglycemia was comparable. Total and basal insulin doses/kgBW were higher in patients with Gla-300. DPV/DIVE subjects were older, had a lower BW, and were more frequently male compared to EDITION patients. HbA 1C was higher in T1D patients from DPV/DIVE.
Conclusion: Data from the diabetes registries DPV/DIVE indicate differences between Gla-300 and Gla-100 patients at the onset of insulin therapy. This analysis provides additional information to the EDITION clinical study program.
Databáze: MEDLINE
Externí odkaz: